Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Stem-like T cells could aid immunotherapy in cancer treatment

Written by | 12 Sep 2021

In a new study by Yale Cancer Center, researchers show stem-like T cells within certain lymph nodes could be natural cancer fighters. Targeting these T cells, which are… read more.

Making CAR-T therapy most effective in leukaemia patients

Written by | 5 Sep 2021

Too many “exhausted” T cells left in the wake of aggressive chemotherapy regimens for patients with advanced chronic lymphocytic leukaemia (CLL) make it more challenging for chimeric antigen… read more.

FDA grants Tecentriq sLBA priority review in non-small cell lung cancer – Genentech/Roche

Written by | 21 Aug 2021

Genentech/Roche announced that the FDA has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq (atezolizumab) as adjuvant treatment following surgery and platinum-based… read more.

BMS statement on Istodax for relapsed/refractory peripheral T-cell lymphoma FDA Indication

Written by | 12 Aug 2021

In 2011, Celgene Corporation, now a wholly owned subsidiary of Bristol Myers Squibb, received accelerated approval by the FDA for Istoda (romidepsin), a histone deacetylase (HDAC) inhibitor, as… read more.

Health Canada approves Brukinsa to treat Mantle Cell Lymphoma – BeiGene

Written by | 4 Aug 2021

BeiGene, Ltd. a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, announced that Brukinsa (zanubrutinib) has… read more.

Merck Inc announces phase III KEYNOTE-826 trial met dual primary endpoints of overall survival and progression-free survival in patients with persistent, recurrent or metastatic cervical cancer

Written by | 2 Jul 2021

Merck Inc., announced that the pivotal Phase III KEYNOTE-826 trial investigating Keytruda, Merck’s anti-PD-1 therapy, in combination with platinum-based chemotherapy (paclitaxel plus cisplatin or paclitaxel plus carboplatin) with… read more.

Study sheds light on treatment options for devastating childhood brain cancer

Written by | 1 Jul 2021

Medulloblastoma is a rare but devastating childhood brain cancer. This cancer can spread through the spinal fluid and be deposited elsewhere in the brain or spine. Radiation therapy… read more.

FDA oncological drugs advisory committee votes in support of Tecentriq in bladder cancer – Genentech/Roche

Written by | 4 May 2021

Genentech/Roche announced the FDA Oncologic Drugs Advisory Committee voted 10 to 1 in favor of maintaining accelerated approval of Tecentriq (atezolizumab) for the treatment of adults with locally… read more.

Major step forward in treatment of multiple myeloma

Written by | 19 Apr 2021

Article by Bruce Sylvester A CAR (chimeric antigen receptor) T-cell therapy (idecabtagene vicleucel) more than triples the expected length of remission for multiple myeloma patients who have relapsed… read more.

EMA validates MAA for Trodelvy under accelerated review in triple-negative breast cancer – Gilead Sciences

Written by | 6 Apr 2021

Gilead Sciences announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for Trodelvy (sacituzumab govitecan-hziy) (SG) for the treatment of adult patients with… read more.

1 in 8 patients with cancer harbour inherited genetic mutations

Written by | 12 Dec 2020

Genetic testing can uncover inherited genetic mutations, and could individualize cancer therapies, improve survival, manage cancer in loved ones and push the boundaries of precision medicine.

Lessons from covid-19: Redesigning oncology pharmacy services for patient safety

Written by | 28 Sep 2020

Interview and article by Christine Clark Modifications of cancer treatment regimens to reduce time spent in hospital, a drive-through pharmacy service and a technician-led virtual counselling clinic were… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.